Science & technology
Our pipeline
SARS

SARS investigational vaccine

Paused developmental vaccine candidates
Severe Acute Respiratory Syndrome (SARS) Vaccine Details
Therapeutic area
Infectious disease
Status
Technology
Respiratory diseases
Severe Acute Respiratory Syndrome (SARS)
 
Preclinical
Therapeutic area
Respiratory diseases
Infectious disease
Severe Acute Respiratory Syndrome (SARS)
Status
 
Preclinical
Technology

About the candidate

Our Severe Acute Respiratory Syndrome (SARS) investigational vaccine is a coronavirus spike protein nanoparticle that works in concert with our Matrix-M™ adjuvant.

Why it matters

While COVID-19 is the most pressing global threat today, less common coronaviruses also take a toll on global populations. These include MERS, which has a fatality rate of 35% and has been reported in 27 countries since 2012,1 and SARS, which has a low fatality rate but is highly transmissible.2 These coronaviruses also demand effective vaccines to help prevent future outbreaks.

  1. Middle Eastern Respiratory Syndrome. WHO. Available at: https://www.who.int/health-topics/middle-east-respiratory-syndrome-coronavirus-mers#tab=tab_1 [Accessed 3 Sept 2021].
  2. Severe Acute Respiratory Syndrome (SARS). WHO. Available at: https://www.who.int/health-topics/severe-acute-respiratory-syndrome#tab=tab_1 [Accessed 3 Sept 2021].
Clinical trials
More about the disease